Myths and truths of growth hormone and testosterone therapy in heart failure
| Autor: | Megha Agarwal, Alistair J Aaronson, Cam T Nguyen, Ryan P. Morrissey, Ernst R. Schwarz, Robert D Willix |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Hemodynamics Internal medicine Internal Medicine medicine Animals Humans Testosterone Hormone replacement therapy Heart Failure business.industry General Medicine Prognosis medicine.disease Myocardial Contraction Clinical trial Endocrinology medicine.anatomical_structure Growth Hormone Heart failure Quality of Life Cardiology Vascular resistance Vascular Resistance Cardiology and Cardiovascular Medicine business Hormone |
| Zdroj: | Expert Review of Cardiovascular Therapy. 9:711-720 |
| ISSN: | 1744-8344 1477-9072 |
| Popis: | Heart failure is a chronic clinical syndrome with very poor prognosis. Despite being on optimal medical therapy, many patients still experience debilitating symptoms and poor quality of life. In recent years, there has been a great interest in anabolic hormone replacement therapy - namely, growth hormone and testosterone - as an adjunctive therapy in patients with advanced heart failure. It has been observed that low levels of growth hormone and testosterone have been associated with increased mortality and morbidity in patients with heart failure. Animal studies and clinical trials have shown promising clinical improvement with hormonal supplementation. Growth hormone has been shown to increase ventricular wall mass, decrease wall stress, increase cardiac contractility, and reduce peripheral vascular resistance, all of which might help to enhance cardiac function, resulting in improvement in clinical symptoms. Likewise, testosterone has been shown to improve hemodynamic parameters via reduction in peripheral vascular resistance and increased coronary blood flow through vasodilation, thereby improving functional and symptomatic status. To date, growth hormone and testosterone therapy have shown some positive benefits, albeit with some concerns over adverse effects. However, large randomized controlled trials are still needed to assess the long-term safety and efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|